Join

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

  • Hyperscale Data Inc. logo
    PR··Technology·
    Hyperscale Data Announces Transaction with Yorkville

    LAS VEGAS, June 11, 2026 /PRNewswire/ -- Hyperscale Data, Inc. (NYSE:GPUS), an artificial intelligence ("AI") data center company anchored by Bitcoin ("Hyperscale Data" or the "Company"), announced that it has entered into a Pre-Paid Advance Agreement (the "Agreement") with YA II PN, Ltd., a Cayman Islands exempt limited partnership ("Yorkville"). Pursuant to the Agreement, Yorkville will today make an advance (the "Advance") to the Company in the principal amount of $15,958,000 (the "Principal Face Amount"), subject to a discount of 6% for an actual commitment amount of $15,000,520. The Advance will bear interest at an annual

  • TechTarget Inc. logo
    PR··Telecommunications·
    Omdia Appoints Theresa Lanowitz as Principal Analyst for Vulnerability and Risk Management

    Omdia has appointed Theresa Lanowitz as Principal Analyst covering vulnerability and risk management within its Cybersecurity go-to-market research practice, bringing decades of experience in software development, industry analysis, and cybersecurity leadership to the role. Lanowitz joins Omdia from LevelBlue, the AT&T cybersecurity spinoff, where she served as Chief Evangelist, leading strategic marketing, communications, public relations, content, and industry outreach. Prior to LevelBlue, she spent seven years at Gartner, leading research on application quality and security, and later founded and led the independent analyst firm Voke for nearly 14 years. At Omdia, Lanowitz will focus

  • Northern Trust Corporation logo
    PR··Finance·
    Northern Trust Asset Management Launches Sustainable Multifactor Funds

    UCITS Funds Provide Climate Focused Core Equities Strategies Northern Trust Asset Management, a leading global investment manager with US$1.4 trillion in assets under management (as of March 31, 2026), today announced the launch of two actively managed UCITS funds, designed to pursue outperformance while efficiently managing climate transition-related risks and opportunities. The NT World Multifactor Focus Select Fund seeks excess returns over a full market cycle, while the NT World Multifactor Select Fund strategy aims to deliver long-term capital growth. Both funds are actively managed using Northern Trust Asset Management's proprietary value, quality, momentum and low volatility sign

  • Oculis Holding AG logo
    PR··Health Care·
    Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

    ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada. Oculis is a proud sponsor of Clinical Trials at the Summit 2026, which brings together experts from around the world to discuss ongoing clinical trials and the latest data, all with the goal of achieving advances in vitreoretinal care. Details of Oculis' presentation are as follo

  • CoreWeave Inc. logo
    PR··Technology·
    CoreWeave Announces Intention to Offer $3.5 Billion of Senior Notes

    CoreWeave, Inc. (Nasdaq: CRWV) ("CoreWeave") announced today that it intends, subject to market and other customary conditions, to offer $3.5 billion (or euro equivalents) in aggregate principal amount of dollar-denominated and euro-denominated senior notes due 2032 (collectively, the "Notes") in a private offering. The Notes will be guaranteed on a senior unsecured basis by certain wholly-owned subsidiaries of CoreWeave. CoreWeave intends to use the proceeds from the offering of the Notes for general corporate purposes, including, without limitation, repayment of outstanding indebtedness, and to pay fees, costs and expenses in connection with the offering of the Notes. The Notes and re

  • Infosys Limited logo
    PR··Technology·
    IHH Healthcare Collaborates with Infosys on a Multi-Country, AI-Powered ERP Transformation to Accelerate Growth

    Powered by Infosys Topaz, the collaboration will help unify operations, optimize processes, and enable a future ready healthcare enterpriseBENGALURU, India and KUALA LUMPUR, Malaysia and SINGAPORE, June 11, 2026 /CNW/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE:INFY), a global leader in AI–first business consulting and technology services, today announced a strategic collaboration with IHH Healthcare, one of the world's largest private healthcare providers, to drive a multi–year, enterprise–wide ERP transformation program. This collaboration will enable IHH to standardize and harmonize business processes across all its markets starting with Hong Kong, Malaysia, and Singapore. It will help strea

  • Cellectis S.A. logo
    PR··Health Care·
    Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

    NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress. BALLI-01 clinical trial evaluating la

  • Johnson & Johnson logo
    PR··Health Care·
    IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

    Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c More patients treated with IMAAVY experienced improvement in fatigued and corticosteroid dose reductionse IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function Pivotal results will be presented at EHA 2026 STOCKHOLM, June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistica

  • Vertex Pharmaceuticals Incorporated logo
    PR··Health Care·
    Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

    - Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older - - Data simultaneously published in the New England Journal of Medicine - - Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 year

  • Evaxion A/S logo
    PR··Health Care·
    Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

    EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and induce targeted cell-killing Poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conv

  • ACI Worldwide Inc. logo
    PR··Technology·
    ACI Worldwide Powers Next-Generation PSP Expansion in Africa with Kwik Payments Go-Live

    Kwik Payments utilizes ACI's Payments Orchestration Platform to help merchants reduce checkout friction and drive conversion uplifts of more than 20% ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, today announced that Kwik Payments, a South Africa-based payments service provider (PSP), has successfully gone live on the ACI Payments Orchestration Platform, to power the next phase of digital commerce growth across South Africa and the wider African market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610062114/en/ The partnership represents a pivotal milestone in ACI's expansion across Afr

  • PureCycle Technologies Inc. logo
    PR··Industrials·
    PureCycle Announces Pricing of Concurrent Public Offerings of 4.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $395.0 Million

    ORLANDO, June 11, 2026 (GLOBE NEWSWIRE) -- PureCycle Technologies, Inc. ("PureCycle" or "we," "our" or "us") (NASDAQ:PCT) today announced the pricing of its previously announced underwritten public offerings of $250.0 million aggregate principal amount of its 4.75% convertible senior notes due 2032 (the "notes" and such offering, the "Notes Offering"), and, concurrently, 17,661,388 shares of its common stock, par value $0.001 per share (the "common stock"; such offering, the "Common Stock Offering" and, together with the Notes Offering, the "Offerings"), at a public offering price of $8.21 per share, for aggregate gross proceeds of $395.0 million. In addition, PureCycle has granted (i) the

  • BW LPG Limited logo
    PR··Consumer Discretionary·
    BW LPG Limited – Ex-dividend on the Oslo Stock Exchange Today

    With reference to the press release dated 2 June 2026 by BW LPG Limited ("BW LPG" or the "Company", OSE ticker code: "BWLPG.OL", NYSE ticker code "BWLP") on key information relating to the cash dividend for Q1 2026, the shares of the Company will be traded ex-dividend on the Oslo Stock Exchange from today and on the New York Stock Exchange from 12 June 2026. The dividend amount is NOK 6.1960 and US$0.67 respectively. About BW LPG BW LPG is the world's leading owner and operator of LPG vessels, with a fleet of about 50 Very Large Gas Carriers (VLGCs), including over 20 vessels powered by LPG dual-fuel propulsion technology. Building on over five decades of LPG shipping experience, the co

  • Fitness Champs Holdings Limited logo
    PR··Consumer Discretionary·
    FCHL to Hold Extraordinary General Meeting on June 29, 2026

    SINGAPORE, June 10, 2026 (GLOBE NEWSWIRE) -- Fitness Champs Holdings Limited ("Fitness Champs Holdings", "FCHL" or the "Company") (NASDAQ:FCHL), a distinguished aquatic sports education provider in Singapore, will hold an Extraordinary General Meeting of Shareholders (the "EGM") at 7030 Ang Mo Kio Street, Avenue 5, #04-48, North Star@AMK, Singapore at 10 a.m. Singapore Time on June 29, 2026 (10 p.m. Eastern Standard Time on June 28, 2026). Holders of the Company's class A ordinary shares (the "Class A Ordinary Shares") and class B ordinary shares (the "Class B Ordinary Shares" and, together with the Class A Ordinary Shares, the "Ordinary Shares") listed in the register of members of the C

  • Humacyte Inc. logo
    PR··Health Care·
    Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

    DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition,

  • First Majestic Silver Corp. logo
    PR··Basic Materials·
    First Majestic Announces Voting Results from 2026 Annual General Meeting

    Vancouver, British Columbia--(Newsfile Corp. - June 10, 2026) - First Majestic Silver Corp. (NYSE:AG) (TSX:AG) (FSE: FMV) (the "Company" or "First Majestic") is pleased to announce the voting results for its Annual General Meeting of shareholders that was held on Wednesday, June 10, 2026 in Vancouver, British Columbia (the "2026 AGM"). Each of the matters that were voted upon at the 2026 AGM are described in detail in the Company's Management Information Circular dated April 29, 2026 (the "Circular"), which is available on the Company's website at www.firstmajestic.com/investors/agm-materials/ and under the Company's profile on SEDAR+ at www.sedarplus.ca.A total of 290,164,319 common shares

  • Afya Limited logo
    PR··Real Estate·
    Afya Limited Releases 2025 Integrated Report

    Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announces the release of its 2025 Integrated Report. The document presents Afya's trajectory throughout 2025, representing the Company's best operational performance since IPO, and marks the full adoption of the Integrated Reporting framework, providing an integrated view of the Company's performance, strategy, and value creation. This edition also includes a new chapter on technology and Artificial Intelligence, outlining how Afya is integrating AI into its medical education and healthcare solutions through dedicated governance and sele

  • Five Star Bancorp logo
    PR··Finance·
    Five Star Bancorp Names Cliff Cooper as Executive Vice President / Food, Agribusiness & Diversified Industries President

    RANCHO CORDOVA, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Five Star Bancorp (NASDAQ:FSBC) ("Five Star" or the "Company"), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank, has announced the promotion of Cliff Cooper to Executive Vice President / Food, Agribusiness & Diversified Industries President. Cooper has over 35 years of banking expertise in food and agribusiness, with a passion for providing the most exceptional banking services available to those who feed our nation. Since 2025, Cooper has led Five Star Bank's Food, Agribusiness & Diversified Industries vertical, which provides exceptional support to clients in production agriculture, who

  • Walker & Dunlop Inc logo
    PR··Finance·
    Walker & Dunlop Hospitality Outlook Shows Investors Continue to Push towards Leisure and Luxury Assets

    Firm Expands Hospitality Advisory Platform Amid Growing Investor Demand for Specialized Expertise Walker & Dunlop, Inc. today released its first Hospitality Outlook, "Capital, Divergence, and the Search for Durable Returns." The new report illustrates how hotel investors are concentrating capital in luxury and upscale leisure properties while new development remains difficult as financing costs remain elevated and underwriting standards tighten. The outlook finds a widening divide across the lodging sector with performance increasingly determined by asset quality, location and traveler demographics rather than broader market trends. The increasingly selective investment environment has

  • Green Brick Partners Inc. logo
    PR··Consumer Discretionary·
    Atlanta St. Jude Dream Home® Open for Tours

    One Lucky Ticket Buyer Will Win a Brand-New Home Built by The Providence Group The Providence Group, a subsidiary of Green Brick Partners, Inc (NYSE:GRBK) and one of metro Atlanta's leading lifestyle homebuilders, along with dozens of generous trade partners, suppliers and sponsors, has completed the 2026 Atlanta St. Jude Dream Home® Giveaway house and is inviting the public to tour the home during select open house weekends this June. Located at 604 Silva Street in The Providence Group's Palisades community in Cumming, the 2026 Dream Home showcases the award-winning builder's commitment to exceptional design, craftsmanship and livable luxury while helping support the lifesaving mission